Our analysis revealed that expression of LAGE3 is significantly higher in triple-negative breast cancer (TNBC) when compared with hormone receptor-positive patients in TCGA (p = 0.0001) and METABRIC datasets (p = 0.017), but we didn’t find significant difference of LAGE3 expression between TNBC and HER2-positive subtype (Figure 8A). The gene discussed is LAGE3; the disease is triple-negative breast carcinoma.